País: Canadá
Língua: inglês
Origem: Health Canada
LOPERAMIDE HYDROCHLORIDE
VITA HEALTH PRODUCTS INC
A07DA03
LOPERAMIDE
2MG
TABLET
LOPERAMIDE HYDROCHLORIDE 2MG
ORAL
6/24/42/84
OTC
ANTIDIARRHEA AGENTS
Active ingredient group (AIG) number: 0111332001; AHFS:
APPROVED
2004-09-20
PRODUCT MONOGRAPH DIARRHEA RELIEF (Loperamide Hydrochloride Tablets USP) 2 mg Caplets ORAL ANTIDIARRHEAL AGENT VITA HEALTH PRODUCTS INC. Date of Preparation: 150 Beghin Avenue September 23, 2004 Winnipeg, MB R2J 3W2 Date of Revision: August 10, 2022 Control # 263048 _ _ _DIARRHEA RELIEF_ _ _ _Product Monograph Page 2 of 30 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ........................................................... 3 SUMMARY PRODUCT INFORMATION ..................................................................................... 3 INDICATIONS AND CLINICAL USE ........................................................................................... 3 CONTRAINDICATIONS ................................................................................................................ 4 WARNINGS AND PRECAUTIONS ............................................................................................... 4 ADVERSE REACTIONS ................................................................................................................. 6 DRUG INTERACTIONS ................................................................................................................. 9 DOSAGE AND ADMINISTRATION ........................................................................................... 10 OVERDOSAGE ............................................................................................................................. 11 ACTION AND CLINICAL PHARMACOLOGY ......................................................................... 12 STORAGE AND STABILITY ....................................................................................................... 13 SPECIAL HANDLING INSTRUCTIONS .................................................................................... 13 DOSAGE FORMS, COMPOSITION AND PACKAGING .......................................................... 14 PART II: SCIENTIFIC INFORMATION ................................................................................. 15 P Leia o documento completo